Clinical Trial Results:
A BLINDED PHASE I/II DOSE ESCALATION STUDY TO ASSESS SAFETY AND IMMUNOGENICITY AND INVESTIGATE THE OPTIMAL DOSE LEVEL OF A FORMALIN-TREATED, UV-INACTIVATED, VERO CELL-DERIVED ROSS RIVER VIRUS (RRV) VACCINE IN HEALTHY VOLUNTEERS AGED 18 TO 40 YEARS
Summary
|
|
EudraCT number |
2008-001774-32 |
Trial protocol |
BE AT NL |
Global completion date |
17 Apr 2009
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Jun 2019
|
First version publication date |
15 Jun 2019
|
Other versions |
|
Summary report(s) |
2008-001774-32 |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.